Cinryze
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- Cinryze
- Generic name
- HUMAN C1-ESTERASE INHIBITOR
- Manufacturer
- Takeda Pharmaceuticals America, Inc.
- Product type
- PLASMA DERIVATIVE
- SPL set ID
- d53a911f-070d-498a-8a61-baab72b9d0fe
- SPL ID
- 421ea216-278f-4ca8-ae5d-5dafe85658a0
- Version
- 42
- Effective date
- 2025-11-28
- Source export date
- 2026-11-13
- Source partition
- 7
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0007-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-11-13/875ce92e4370b2000cf566c8a9c0e4d02cceccd3a3b18a8b0b87928b28506f0b/drug-label-0007-of-0014.json.zip
- Source manifest SHA-256
- 8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
- Import run
- 20261116T150851Z
- Imported at
- 2026-11-16 16:35:17
| Harmonized routes |
|---|
| INTRAVENOUS |
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| application applno | BLA | 125267 | derived:openfda.application_number |
| application number | BLA125267 | openfda.application_number | |
| brand name | Cinryze | openfda.brand_name | |
| generic name | HUMAN C1-ESTERASE INHIBITOR | openfda.generic_name | |
| manufacturer name | Takeda Pharmaceuticals America, Inc. | openfda.manufacturer_name | |
| ndc | package | 42227-081-01 | openfda.package_ndc |
| ndc | package | 42227-083-01 | openfda.package_ndc |
| ndc | package | 64764-515-50 | openfda.package_ndc |
| ndc | product | 42227-083 | openfda.product_ndc |
| ndc | product | 42227-081 | openfda.product_ndc |
| ndc11 | package | 42227008301 | derived:openfda.package_ndc |
| ndc11 | package | 64764051550 | derived:openfda.package_ndc |
| ndc11 | package | 42227008101 | derived:openfda.package_ndc |
| rxcui | 809871 | openfda.rxcui | |
| rxcui | 1729336 | openfda.rxcui | |
| spl id | 421ea216-278f-4ca8-ae5d-5dafe85658a0 | id | |
| spl set id | d53a911f-070d-498a-8a61-baab72b9d0fe | set_id | |
| unii | 6KIC4BB60G | openfda.unii |
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
5 WARNINGS AND PRECAUTIONS Hypersensitivity reactions may occur. Have epinephrine immediately available for treatment of acute severe hypersensitivity reaction ( 5.1 ) Serious arterial and venous thromboembolic (TE) events have been reported at the recommended dose of C1 esterase inhibitor (human) products, including CINRYZE, following administration in patients with HAE. Risk factors may include presence of an indwelling venous catheter/access device, prior history of thrombosis, underlying atherosclerosis, use of oral contraceptives, certain androgens, morbid obesity, and immobility. Benefits of CINRYZE for routine prophylaxis of HAE attacks should be weighed against the risks of TE events in patients with underlying risk factors. Monitor patients with known risk factors for TE events during and after CINRYZE administration. TE events have been reported following administration of a C1 esterase inhibitor (human) product when used off-label at higher than labeled doses. ( 5.2 ) CINRYZE is made from human plasma and may contain infectious agents e.g., viruses and, theoretically, the Creutzfeldt-Jakob disease agent. ( 5.3 ) 5.1 Hypersensitivity Reactions Severe hypersensitivity reactions may occur. The signs and symptoms of hypersensitivity reactions may include the appearance of hives, urticaria, tightness of the chest, wheezing, hypotension and/or anaphylaxis experienced during or after injection of CINRYZE. Consider treatment methods carefully because hypersensitivity reactions may have symptoms similar to HAE attacks. In case of hypersensitivity, discontinue CINRYZE infusion and institute appropriate treatment. Have epinephrine immediately available for treatment of acute severe hypersensitivity reaction. [see Patient Counseling Information (17) ] . 5.2 Thromboembolic Events Serious arterial and venous thromboembolic (TE) events have been reported at the recommended dose of C1 esterase inhibitor (human) products, including CINRYZE, following administration in patients with HAE. Risk factors may include presence of an indwelling venous catheter/access device, prior history of thrombosis, underlying atherosclerosis, use of oral contraceptives, certain androgens, morbid obesity, and immobility. Benefits of CINRYZE for routine prophylaxis of HAE attacks should be weighed against the risks of TE events in patients with underlying risk factors. Monitor patients with known risk factors for TE events during and after CINRYZE administration. TE events have been reported following administration of a C1 esterase inhibitor (human) product when used off-label at higher than labeled doses 1 . In an open-label trial further investigating the use of CINRYZE for prevention (n=146) of HAE attacks, 5 serious TE events (including myocardial infarction, deep vein thrombosis, pulmonary embolism and 2 events of cerebrovascular accident) occurred. Subjects had underlying risk factors for TE events. In the post-approval open-label study (n=20) there were no systemic TE events in subjects who received CINRYZE up to 2,500 U (not exceeding 100 U/kg) every 3 or 4 days for up to 12 months. One subject developed a blood clot in an intravenous central catheter, which was treated without systemic complication. [see Adverse Reactions (6.1) ] . 5.3 Transmissible Infectious Agents Because CINRYZE is made from human blood, it may carry a risk of transmitting infectious agents, e.g., viruses, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent [see Description (11) ]. ALL infections thought by a physician possibly to have been transmitted by CINRYZE should be reported by the physician or other healthcare provider to Takeda Pharmaceuticals U.S.A., Inc. [1-877-TAKEDA-7 (1-877-825-3327)]. The physician should discuss the risks and benefits of this product with the patient, before prescribing or administering it to the patient. [see Patient Counseling Information (17) ]
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
6 ADVERSE REACTIONS The most common adverse reactions (≥5%) observed were headache, nausea, rash, vomiting, and fever. The most common adverse reactions (≥5%) observed were headache, nausea, rash, vomiting, and fever. ( 6.1 , 6.2 ) To report SUSPECTED ADVERSE REACTIONS, contact Takeda Pharmaceuticals U.S.A., Inc. at 1-877-TAKEDA-7 (1-877-825-3327) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Twenty-four subjects age 9 to 73 years old were evaluated in the randomized, placebo-controlled, crossover, routine prophylaxis trial. There were no serious adverse reactions in the randomized, placebo-controlled, crossover, routine prophylaxis trial. Adverse reactions in the randomized, placebo-controlled, crossover, routine prophylaxis trial (n=24) that occurred in at least two subjects (≥8%) receiving CINRYZE are given in Table 2: Table 2 Adverse Reactions in the Randomized, Placebo-Controlled, Crossover, Routine Prophylaxis Trial. Adverse Reaction Number of Adverse Reactions Number of Subjects (N = 24) Rash 8 5 Headache 4 4 Pruritus 2 2 Vomiting 2 2 In an open-label follow-on trial, 146 subjects age 3 to 82 years old received a median of 243.5 days of CINRYZE (maximum = 959 days). The most common adverse reaction observed was headache. No subjects were discontinued due to an adverse reaction. Adverse reactions in the open-label follow-on trial (n=146) that occurred in at least three subjects (≥2%) receiving CINRYZE, are given in Table 3: Table 3 Adverse Reactions in the Open-Label Follow-On Trial. Adverse Reaction Number (%) of Subjects (N=146) with Adverse Reaction Number (%) of Infusion Days (N=11,435) with Adverse Reaction Headache 28 (19) 62 (0.5) Nausea 26 (18) 29 (0.3) Rash 15 (10) 30 (0.3) Vomiting 15 (10) 17 (0.1) Pyrexia (fever) 7 (5) 7 (<0.1) Catheter Site Pain 4 (3) 5 (<0.1) Dizziness 3 (2) 4 (<0.1) Erythema 3 (2) 3 (<0.1) Pruritus 3 (2) 4 (<0.1) Serious adverse reactions included cerebrovascular accident [see Warnings and Precautions (5.2) ] . Twelve pediatric subjects age 7 to 11 years old were evaluated in a randomized, dose-ranging, crossover routine prophylaxis trial (500 U and 1,000 U). No new adverse reactions (compared to the placebo-controlled routine prophylaxis trial or the open label follow-on trial) were identified. The adverse reactions among the pediatric subjects were headache, nausea, pyrexia (fever), and infusion site erythema. None of these adverse reactions were severe, and none led to discontinuation of CINRYZE. The safety profile with 500 U or 1,000 U of CINRYZE treatment was comparable. Overall, the safety and tolerability of CINRYZE are similar in pediatric, adolescent, and adult subjects. More than 14,000 doses of CINRYZE have been administered to over 260 different subjects in all completed, controlled and open-label clinical studies. All subjects who were evaluated were found negative for seroconversion to parvovirus B19, Hepatitis B, Hepatitis C and HIV. [see Warnings and Precautions (5.3) ] A post-approval open-label study assessed escalating doses of CINRYZE (1,500 U, 2,000 U, 2,500 U every 3 or 4 days) as prophylactic therapy in 20 subjects who had an inadequate response (> 1.0 HAE attack/month, regardless of severity) to 1,000 U every 3 or 4 days. The safety profile of doses up to 2,500 U was consistent with previous clinical trial experience at lower doses. 6.2 Immunogenicity Because CINRYZE is a therapeutic protein, there is potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of anti-C1 esterase inhibitor antibody positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibody development across products cannot be made. 6.3 Postmarketing Experience Because post marketing reporting of adverse reactions is voluntary and from a population of uncertain size, it is not always possible to reliably estimate the frequency of these reactions or establish a causal relationship to product exposure. Postmarketing adverse reactions included local infusion site reactions (including inflammation or hematoma at the infusion site) and hypersensitivity.
adverse reactions table
<table width="60%"><caption>Table 2 Adverse Reactions in the Randomized, Placebo-Controlled, Crossover, Routine Prophylaxis Trial.</caption><col width="20%" align="left" valign="top"/><col width="40%" align="left" valign="top"/><col width="40%" align="left" valign="top"/><thead><tr><th styleCode="Lrule Rrule">Adverse Reaction</th><th styleCode="Rrule">Number of Adverse Reactions</th><th styleCode="Rrule">Number of Subjects (N = 24)</th></tr></thead><tbody><tr styleCode="Botrule"><td styleCode="Lrule Rrule"><content styleCode="bold">Rash</content></td><td styleCode="Rrule">8</td><td styleCode="Rrule">5</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule"><content styleCode="bold">Headache</content></td><td styleCode="Rrule">4</td><td styleCode="Rrule">4</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule"><content styleCode="bold">Pruritus</content></td><td styleCode="Rrule">2</td><td styleCode="Rrule">2</td></tr><tr><td styleCode="Lrule Rrule"><content styleCode="bold">Vomiting</content></td><td styleCode="Rrule">2</td><td styleCode="Rrule">2</td></tr></tbody></table>
adverse reactions table
<table width="65%"><caption>Table 3 Adverse Reactions in the Open-Label Follow-On Trial.</caption><col width="20%" align="left" valign="top"/><col width="40%" align="left" valign="top"/><col width="40%" align="left" valign="top"/><thead><tr><th styleCode="Lrule Rrule">Adverse Reaction</th><th styleCode="Rrule">Number (%) of Subjects (N=146) with Adverse Reaction</th><th styleCode="Rrule">Number (%) of Infusion Days (N=11,435) with Adverse Reaction</th></tr></thead><tbody><tr styleCode="Botrule"><td styleCode="Lrule Rrule"><content styleCode="bold">Headache</content></td><td styleCode="Rrule">28 (19)</td><td styleCode="Rrule">62 (0.5)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule"><content styleCode="bold">Nausea</content></td><td styleCode="Rrule">26 (18)</td><td styleCode="Rrule">29 (0.3)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule"><content styleCode="bold">Rash</content></td><td styleCode="Rrule">15 (10)</td><td styleCode="Rrule">30 (0.3)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule"><content styleCode="bold">Vomiting</content></td><td styleCode="Rrule">15 (10)</td><td styleCode="Rrule">17 (0.1)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule"><content styleCode="bold">Pyrexia (fever)</content></td><td styleCode="Rrule">7 (5)</td><td styleCode="Rrule">7 (<0.1)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule"><content styleCode="bold">Catheter Site Pain</content></td><td styleCode="Rrule">4 (3)</td><td styleCode="Rrule">5 (<0.1)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule"><content styleCode="bold">Dizziness</content></td><td styleCode="Rrule">3 (2)</td><td styleCode="Rrule">4 (<0.1)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule"><content styleCode="bold">Erythema</content></td><td styleCode="Rrule">3 (2)</td><td styleCode="Rrule">3 (<0.1)</td></tr><tr><td styleCode="Lrule Rrule"><content styleCode="bold">Pruritus</content></td><td styleCode="Rrule">3 (2)</td><td styleCode="Rrule">4 (<0.1)</td></tr></tbody></table>
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.